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ABSTRACT 
Introduction: This study is a secondary data analysis of HIV/AIDS patients on Anti-
retroviral Therapy (ART), at Themba Lethu HIV/AIDS clinic, who have had the first 
break in the continuity of taking their Antiretrovirals (ARVs) of more than 10 days, 
measured by patient missing the refill appointment for more than 10 days. The 
clinic started in 2004. HIV/AIDS is high in South Africa with about 400,000 AIDS 
patients on ARVs. For ARVs to be most effective they must be taken continuously 
without breaks, and for life. Without this, there is risk of ARVS drug resistance 
development and consequent failure of the ART program. Some patients may break 
this continuity and this seems to be a problem in South Africa. Where the patients 
develops side-effects or is not responding well to treatment, clinicians may also 
cause a break in the therapy. This study described the first break as when it 
occurred and for how long it lasted, investigated the factors associated with this 
break and the association of the first break and the last CD4 count.  
 
Materials and methods:  7,930 adults (≥18 years, either gender) on ART and 
baseline CD4 <250 cells/µl  were included in the study. The study group  were 
patients who had first break in continuity of therapy of more than 10 days. The first 
break was described as when  it occurred after months of ART initiation and how 
long(days)  the first break lasted.  Patients on Post- Exposure Prophylaxis, single-
dose Nevirapine, Prevention-of mother-To-Child- transmission therapy, and those 
with breaks in therapy of more than 364 days were excluded. Outcome variables 
was the last CD4 count. Analyses were in STATA 10, at 95% confidence interval. 
Median and quartile ranges  were used to describe participants in the study. T-test, 
Fishers exact test and chi-square were used to compare groups. Regression was 
used to determine demographic and clinical  factors associated with first break in 
therapy and also   to determine the association of first break in therapy and the last 
CD4  count.  
 
Results: The median duration on ART for the patients was 764 days. 63% of 
patients had a break in ART.  47.5% of patients had their first break in therapy 
 v 
within the first 2 years of being on the ART program, with the largest proportion 
within the first 6 months of therapy. Most patient came with advanced disease(CD4 
<100cells/µl, WHO clinical staging IV). Women were twice more than men. They 
tended to come earlier for therapy, took longer to improve and delayed in having 
the first break compared to men (254 vs. 205  days). Baseline hemoglobin and 
unemployment were factors associated with when  the first break occurred. The 
median length of first break was 21 (Q1-Q3 7-43) Unemployment and baseline 
hemoglobin were associated with length of first break. The first break in therapy 
was associated with the last CD4 count. The longer the patient stayed on ART 
without the first break, the higher the last CD4 would be. Peripheral neuropathy had 
a statistically significant positive association with the last CD4 count. However, 
baseline CD4, Age, baseline BMI, WHO stage IV, baseline hemoglobin and 
unemployment had a statistically significant but negative association with the last 
CD4 count. The weakness of using the missing appointment system is that it does 
not inform clinician whether patients is really taking or not taking ARVs at home. Its 
strength over the self reported adherence system is that it is free of recall bias.  
 
Conclusion: Though Themba Lethu clinic has a follow-up system in place for 
patients missing refill appointment,  up to 63% patient missed their appointment to 
collect medicine on time and this had a negative effect on the last CD4. There is need 
to strengthen existing follow-up method besides decentralising the ART services in 
Johannesburg.  
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DEFINITIONS 
 
ART: Antiretroviral Therapy 
 
ARVs: Antiretrovirals; Medicines used to treat HIV/AIDS 
 
Last CD4: The CD4 which was recorded just before data was abstracted 
Break: This is period, in days, from the time the ARVs were interrupted for more  
than 10 days, for any reason, to the time the patient resumes taking ARV 
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